Generic liraglutide: what TikTok gets wrong about availability

What did @kummdogmillionaire actually say?

The creator made a straightforward case: generic liraglutide is a real, available GLP-1 option that gets overlooked in the semaglutide and tirzepatide hype. They named the brand equivalents (Victoza for diabetes, Saxenda for weight loss), explained the mechanism, and pointed to actual clinical trials. They were careful to say semaglutide and tirzepatide outperform liraglutide, but argued liraglutide still delivers "clinically significant outcomes" for glycemic control, weight loss, and cardiovascular protection.

They cited three trials by name: SCALE (weight loss), LEADER (cardiovascular and renal outcomes), and STARDUST (peripheral artery disease and limb perfusion). The framing was patient-centered, pointing to insurance coverage and side effect management as reasons liraglutide deserves consideration. That is a more nuanced take than most TikTok GLP-1 content, and it is worth examining whether the science actually backs it up.

Does the science back this up?

Mostly, yes. The trials they cited are real and the findings are accurately characterized, though some details are imprecise. The LEADER trial (Marso et al., 2016, NEJM) did show significant cardiovascular benefit with liraglutide in high-risk type 2 diabetes patients, including reduced rates of major adverse cardiovascular events and some renal protective effects. That is not disputed.

The SCALE trial (Pi-Sunyer et al., 2015, NEJM) showed liraglutide 3.0 mg produced roughly 8% mean weight loss versus 2.6% for placebo. The claim that "some participants had greater than 10% weight loss" is technically true but cherry-picks the high end of the distribution rather than the average. The STARDUST trial (Bonaca et al., 2022, Circulation) is a smaller study looking at liraglutide in peripheral artery disease. The limb perfusion finding is real but preliminary and based on a phase 2 trial, not a large outcomes study. Citing it alongside LEADER and SCALE as equivalent evidence is a stretch.

What did they get wrong (or right)?

The mechanism description has a significant error. The creator said liraglutide works by "reducing gastric motility and delaying gastric emptying and disrupting the appetite signal in the brain and in turn, increasing the amount of insulin." That sequence is backwards. Liraglutide primarily works by binding GLP-1 receptors in the pancreas to stimulate glucose-dependent insulin secretion and suppress glucagon. Delayed gastric emptying and appetite suppression are real secondary effects, but listing them as the primary mechanism before insulin effects misrepresents the pharmacology (Drucker, 2018, Cell Metabolism).

What they got right: the comparative efficacy framing is accurate. Semaglutide and tirzepatide do produce more weight loss and better glycemic outcomes in head-to-head data. Liraglutide still produces clinically meaningful results. The insurance and tolerability angle is legitimate clinical reasoning. Starting patients on liraglutide before escalating is a real practice some clinicians use for GI side effect management, though this is not formally established in major guidelines.

What should you actually know?

Generic liraglutide (the active ingredient in Victoza and Saxenda) became available in the US starting in 2024. It is not a compounded drug. It is an FDA-approved generic of an approved branded product, which is a different regulatory category from the compounded semaglutide currently circulating in the market. That distinction matters enormously for safety and efficacy expectations.

The claim to "check with your insurance" is reasonable general advice, but coverage for the generic varies widely. Some plans cover the diabetes indication (Victoza equivalent) but not the weight loss indication (Saxenda equivalent), and the dosing differs between the two. A patient checking coverage without specifying the indication and dose could get misleading information. If you are considering any GLP-1 therapy, that conversation needs to happen with a licensed prescriber who knows your full medical history, not a TikTok comment section.

Bottom line on this video

This is one of the more clinically grounded GLP-1 videos circulating on TikTok right now. The creator got the big picture right, cited real trials, and avoided the typical overclaiming. The mechanism description has a meaningful pharmacology error, and leaning on STARDUST as major evidence overstates what is currently a preliminary finding. But the core public service message, that generic liraglutide exists and is worth asking your doctor about, is accurate and useful.